Efficacy of topical steroids in preventing radiation dermatitis: A systematic review and meta‐analysis

To evaluate the relative efficacy of topical steroids in preventing radiation dermatitis (RD). Multiple databases including Medline, Cochrane Library, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), China Biological Medicine (SinoMed), and Wanfang Database were searched for r...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Dermatologic therapy Ročník 35; číslo 12; s. e15918 - n/a
Hlavní autoři: Shao, Xinyi, Chen, Tingqiao, Li, Hao, Chen, Yangmei, Zhang, Yujie, Chen, Jiayi, Li, Yuxin, Liu, Lin, Pu, Yihuan, Chen, Jin
Médium: Journal Article
Jazyk:angličtina
Vydáno: Hoboken, USA John Wiley & Sons, Inc 01.12.2022
Témata:
China
Dermatitis - etiology
Dermatitis - prevention & control
Humans
meta‐analysis
radiation dermatitis
Radiation Therapy Oncology Group
randomized controlled trials
Steroids - therapeutic use
topical steroid
China
meta-analysis
Radiation Therapy Oncology Group
randomized controlled trials
topical steroid
radiation dermatitis
ISSN:1396-0296, 1529-8019, 1529-8019
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:To evaluate the relative efficacy of topical steroids in preventing radiation dermatitis (RD). Multiple databases including Medline, Cochrane Library, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), China Biological Medicine (SinoMed), and Wanfang Database were searched for randomized controlled trials (RCTs) of RD prevention in patients with cancer from inception to November 26, 2021, followed by an update on June 1, 2021. Six RCTs evaluating the efficacy of topical steroids in preventing RD in a total of 661 patients with cancer were included. RD incidence was lower with topical steroids compared with placebo at week 3 (relative risk [RR] = 0.68, 95% confidence interval [CI]: 0.31–1.50) and at radiation therapy (RT) completion (RR = 0.97, 95% CI: 0.93–1.00). Topical steroids demonstrated a less risk of developing dermatitis of Radiation Therapy Oncology Group (RTOG) grades 2 and 3 at the completion of RT (RR = 0.66, 95% CI: 0.55–0.80 and RR = 0.54, 95% CI: 0.38–0.77, respectively). However, topical steroids did not reduce RTOG grades 1 and 2 dermatitis at week 3(RR = 0.73, 95% CI: 0.45–1.14 and RR = 0.66, 95% CI: 0.27–1.60, respectively). Notably, the use of topical steroids did not decrease RD incidence when patients received combined chemotherapy (RR = 0.60, 95% CI: 0.42–0.86), and an obvious reduction in the incidence of RD at RT completion was found when patients used the topical steroids twice‐daily (RR = 0.66, 95% CI: 0.47–0.93, P = 0.02). Topical steroids reduced RD incidence in patients receiving RT. Thus, twice‐daily topical steroids may be recommended for patients at the beginning of RT.
Bibliografie:Funding information
Xinyi Shao and Tingqiao Chen contributed equally to this study.
National Natural Science Foundation of China, Grant/Award Number: n82073462
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-4
content type line 23
ObjectType-Undefined-3
ISSN:1396-0296
1529-8019
1529-8019
DOI:10.1111/dth.15918